Latest Ratios: P/E Ratio -5.2x · EV/EBITDA N/A · ROE -56.2%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $225M | $238M | $186M | $180M | $227M | $230M | $356M | $121M | — | — | — |
| Enterprise Value | $150M | $163M | $136M | $161M | $189M | $164M | $273M | $118M | — | — | — |
| P/E Ratio → | -5.20 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 13.98 | 14.78 | 18.29 | 24.98 | 33.95 | 33.44 | 48.68 | 29.11 | — | — | — |
| P/B Ratio | 2.47 | 2.61 | 3.08 | 5.76 | 4.36 | 2.85 | 3.65 | 8.44 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 10.10 | 13.40 | 22.43 | 28.22 | 23.88 | 37.42 | 28.19 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.8% | 70.8% | 65.9% | 60.9% | 45.2% | 43.0% | 47.6% | 57.3% | 31.7% | 38.2% | — |
| Operating Margin | -256.3% | -256.3% | -309.6% | -397.5% | -480.9% | -440.7% | -258.3% | -357.1% | -776.0% | -451.9% | — |
| Net Profit Margin | -264.4% | -264.4% | -260.4% | -396.8% | -429.1% | -446.7% | -296.0% | -364.7% | -797.9% | -383.8% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -56.2% | -56.2% | -57.8% | -68.7% | -43.3% | -34.5% | -38.7% | -89.7% | -99.0% | -134.3% | -115.1% |
| ROA | -32.4% | -32.4% | -46.4% | -52.7% | -38.0% | -32.1% | -32.1% | -47.4% | -54.1% | -75.2% | -73.8% |
| ROIC | -235.5% | -235.5% | -200.8% | -161.4% | -168.8% | -151.8% | -110.2% | -136.7% | -180.8% | -378.6% | -327.2% |
| ROCE | -33.2% | -33.2% | -62.2% | -58.5% | -45.0% | -33.2% | -31.0% | -59.3% | -70.5% | -127.8% | -110.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.08 | 0.25 | 0.16 | 0.02 | 0.02 | 0.76 | 0.45 | 0.36 | 0.45 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.83 | -0.82 | -0.59 | -0.74 | -0.82 | -0.84 | -0.27 | -0.70 | -0.42 | -0.96 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -36.27 | -168.80 | -459.67 | -38.74 | -13.52 | -18.96 | -12.91 | -25.57 |
Net cash position: cash ($82M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.52 | 12.52 | 10.52 | 6.58 | 14.82 | 18.56 | 20.32 | 2.77 | 4.81 | 1.64 | 4.54 |
| Quick Ratio | 11.17 | 11.17 | 9.64 | 5.48 | 12.92 | 16.78 | 19.22 | 2.33 | 4.35 | 1.51 | 4.46 |
| Cash Ratio | 9.83 | 9.83 | 8.36 | 4.12 | 11.12 | 16.16 | 17.45 | 1.80 | 3.89 | 1.04 | 4.21 |
| Asset Turnover | — | 0.08 | 0.14 | 0.16 | 0.10 | 0.08 | 0.07 | 0.14 | 0.06 | 0.18 | — |
| Inventory Turnover | 0.42 | 0.42 | 0.60 | 0.40 | 0.46 | 0.53 | 0.72 | 0.49 | 0.49 | 2.12 | 0.60 |
| Days Sales Outstanding | — | 223.59 | 252.91 | 369.51 | 346.59 | 74.88 | 371.35 | 289.84 | 289.58 | 334.27 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $30M | $25M | $21M | $21M | $20M | $17M | $11M | $10M | $6M | $4M |
Persistent operational cash burn
Based on current market data, PROF trades at a price-to-sales multiple of 12.22, which suggests that investors are pricing the company as a high-growth disruptor rather than a traditional medical device manufacturer, despite the absence of positive earnings or a meaningful forward price-to-earnings ratio.
The elevated P/S ratio indicates that the market is heavily discounting future revenue growth and the potential for long-term margin expansion. This valuation appears to rely on the assumption that the TULSA-PRO system will achieve widespread clinical adoption, effectively justifying a premium over more mature, profitable peers.
As reported in financial statements, PROF's return on invested capital has remained deeply negative, fluctuating between -36.7% and -114.3% over the last ten quarters, which highlights the significant challenge of generating positive returns while the company is still in the heavy investment phase of its commercial lifecycle.
The persistent negative ROIC suggests that the capital deployed into the business is currently destroying value rather than compounding it. Investors should monitor whether the company can improve its asset turnover and operating margins to move toward a neutral or positive return profile as the installed base matures.
According to recent quarterly filings, PROF's cash conversion cycle has been highly volatile, peaking at 1,867 days in 2024Q1 and remaining elevated, which indicates significant inefficiencies in managing inventory and collecting receivables compared to more established medical device companies with faster turnover rates.
The extended CCC is largely driven by high days inventory outstanding, reflecting the specialized nature of the TULSA-PRO hardware and the time required to place units in clinical settings. This inefficiency suggests that the company's working capital management is currently a drag on liquidity, requiring careful monitoring as the firm attempts to scale.
Based on PROF's reported figures, the company maintains a healthy balance sheet with a debt-to-equity ratio of 0.13 as of 2026Q1, indicating that the firm has avoided significant debt obligations and retains the financial flexibility to fund its operations through equity-based capital raises.
The lack of meaningful debt service requirements is a critical advantage for a company with deeply negative operating margins, as it removes the risk of insolvency during the commercialization phase. This conservative approach appears to be a deliberate strategy to prioritize long-term growth over short-term financial leverage.
The price-to-earnings ratio is the most commonly misapplied metric for PROF, as it obscures the company's true value by focusing on net losses that are heavily influenced by non-cash stock-based compensation and aggressive R&D spending rather than core operational viability.
Investors should instead focus on revenue growth and the utilization rate of the installed base, as these metrics better capture the company's progress toward a sustainable business model. Relying on P/E ratios in this context is misleading because it fails to account for the early-stage nature of the firm's commercial rollout.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PROF stock.
Profound Medical Corp.'s current P/E ratio is -5.2x. This places it at the 50th percentile of its historical range.
Profound Medical Corp.'s return on equity (ROE) is -56.2%. The historical average is -85.8%.
Based on historical data, Profound Medical Corp. is trading at a P/E of -5.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Profound Medical Corp. has 70.8% gross margin and -256.3% operating margin.